Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7NLL

SARS-CoV-2 Spike RBD (dimer) in complex with two Fu2 nanobodies

Summary for 7NLL
Entry DOI10.2210/pdb7nll/pdb
EMDB information12465
DescriptorSpike protein S1, Nanobody Fu2, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
Functional Keywordsnanobody, spike, complex, dimer, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains4
Total formula weight83448.60
Authors
Das, H.,Hallberg, B.M. (deposition date: 2021-02-22, release date: 2022-02-02, Last modification date: 2024-11-13)
Primary citationHanke, L.,Das, H.,Sheward, D.J.,Perez Vidakovics, L.,Urgard, E.,Moliner-Morro, A.,Kim, C.,Karl, V.,Pankow, A.,Smith, N.L.,Porebski, B.,Fernandez-Capetillo, O.,Sezgin, E.,Pedersen, G.K.,Coquet, J.M.,Hallberg, B.M.,Murrell, B.,McInerney, G.M.
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
Nat Commun, 13:155-155, 2022
Cited by
PubMed Abstract: Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike have therapeutic promise, but emerging variants show the potential for virus escape. This emphasizes the need for therapeutic molecules with distinct and novel neutralization mechanisms. Here we describe the isolation of a nanobody that interacts simultaneously with two RBDs from different spike trimers of SARS-CoV-2, rapidly inducing the formation of spike trimer-dimers leading to the loss of their ability to attach to the host cell receptor, ACE2. We show that this nanobody potently neutralizes SARS-CoV-2, including the beta and delta variants, and cross-neutralizes SARS-CoV. Furthermore, we demonstrate the therapeutic potential of the nanobody against SARS-CoV-2 and the beta variant in a human ACE2 transgenic mouse model. This naturally elicited bispecific monomeric nanobody establishes an uncommon strategy for potent inactivation of viral antigens and represents a promising antiviral against emerging SARS-CoV-2 variants.
PubMed: 35013189
DOI: 10.1038/s41467-021-27610-z
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.89 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon